Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CANAGLIFLOZIN Cause Urinary tract infection? 920 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 920 reports of Urinary tract infection have been filed in association with CANAGLIFLOZIN (INVOKANA). This represents 3.8% of all adverse event reports for CANAGLIFLOZIN.

920
Reports of Urinary tract infection with CANAGLIFLOZIN
3.8%
of all CANAGLIFLOZIN reports
16
Deaths
318
Hospitalizations

How Dangerous Is Urinary tract infection From CANAGLIFLOZIN?

Of the 920 reports, 16 (1.7%) resulted in death, 318 (34.6%) required hospitalization, and 26 (2.8%) were considered life-threatening.

Is Urinary tract infection Listed in the Official Label?

Yes, Urinary tract infection is listed as a known adverse reaction in the official FDA drug label for CANAGLIFLOZIN.

What Other Side Effects Does CANAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,413) Toe amputation (2,193) Osteomyelitis (2,146) Acute kidney injury (1,853) Fungal infection (1,385) Gangrene (1,081) Weight decreased (1,014) Cellulitis (1,007) Diabetic foot infection (832) Leg amputation (792)

What Other Drugs Cause Urinary tract infection?

ADALIMUMAB (6,375) LENALIDOMIDE (4,247) ETANERCEPT (3,915) OCRELIZUMAB (3,618) TOFACITINIB (3,179) METHOTREXATE (2,960) DALFAMPRIDINE (2,757) RITUXIMAB (2,579) CARBIDOPA\LEVODOPA (2,151) ABATACEPT (2,110)

Which CANAGLIFLOZIN Alternatives Have Lower Urinary tract infection Risk?

CANAGLIFLOZIN vs CANAGLIFLOZIN\METFORMIN CANAGLIFLOZIN vs CANAKINUMAB CANAGLIFLOZIN vs CANDESARTAN CANAGLIFLOZIN vs CANDESARTAN CILEXETIL CANAGLIFLOZIN vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE

Related Pages

CANAGLIFLOZIN Full Profile All Urinary tract infection Reports All Drugs Causing Urinary tract infection CANAGLIFLOZIN Demographics